147 related articles for article (PubMed ID: 12625813)
1. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease.
Detková Z; Kupcová V; Príkazská M; Turecký L; Weissová S; Jahnová E
Physiol Res; 2003; 52(1):95-100. PubMed ID: 12625813
[TBL] [Abstract][Full Text] [Related]
2. Changes in acute phase proteins after anti-tumor necrosis factor antibody (infliximab) treatment in patients with Crohn's disease.
Kupcová V; Turecký L; Detková Z; Príkazská M; Keleová A
Physiol Res; 2003; 52(1):89-93. PubMed ID: 12625812
[TBL] [Abstract][Full Text] [Related]
3. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
4. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease.
Van den Brande JM; Koehler TC; Zelinkova Z; Bennink RJ; te Velde AA; ten Cate FJ; van Deventer SJ; Peppelenbosch MP; Hommes DW
Gut; 2007 Apr; 56(4):509-17. PubMed ID: 17082252
[TBL] [Abstract][Full Text] [Related]
5. Effect of tumor necrosis factor-α antagonists on oxidative stress in patients with Crohn's disease.
Yamamoto K; Chiba T; Matsumoto T
World J Gastroenterol; 2015 Sep; 21(35):10208-14. PubMed ID: 26401086
[TBL] [Abstract][Full Text] [Related]
6. Peripheral regulatory T cells and serum transforming growth factor-β: relationship with clinical response to infliximab in Crohn's disease.
Di Sabatino A; Biancheri P; Piconese S; Rosado MM; Ardizzone S; Rovedatti L; Ubezio C; Massari A; Sampietro GM; Foschi D; Porro GB; Colombo MP; Carsetti R; MacDonald TT; Corazza GR
Inflamm Bowel Dis; 2010 Nov; 16(11):1891-7. PubMed ID: 20848485
[TBL] [Abstract][Full Text] [Related]
7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
8. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.
Asakura H; Yao T; Matsui T; Koganei K; Fukushima T; Takazoe M; Hobara R; Nakano H; Okamura S; Matsueda K; Kashida H; Makiyama K; Hiwatashi N; Kashiwagi K; Hibi T
J Gastroenterol Hepatol; 2001 Jul; 16(7):763-9. PubMed ID: 11446884
[TBL] [Abstract][Full Text] [Related]
10. Profiles of circulating cytokines in patients with Crohn's disease under maintenance therapy with infliximab.
Ogawa K; Matsumoto T; Esaki M; Torisu T; Iida M
J Crohns Colitis; 2012 Jun; 6(5):529-35. PubMed ID: 22398057
[TBL] [Abstract][Full Text] [Related]
11. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
12. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
Dideberg V; Théâtre E; Farnir F; Vermeire S; Rutgeerts P; De Vos M; Belaiche J; Franchimont D; Van Gossum A; Louis E; Bours V
Pharmacogenet Genomics; 2006 Oct; 16(10):727-34. PubMed ID: 17001292
[TBL] [Abstract][Full Text] [Related]
13. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
[TBL] [Abstract][Full Text] [Related]
14. The role of oxidative stress in anti-tumor necrosis factor antibody treatment in Crohn's disease.
Kupčova V; Tureckỳ L; Uhlíkova E
Curr Med Chem; 2012; 19(30):5226-31. PubMed ID: 23061628
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.
Bouchaud G; Mortier E; Flamant M; Barbieux I; Plet A; Galmiche JP; Jacques Y; Bourreille A
Gastroenterology; 2010 Jun; 138(7):2378-87. PubMed ID: 20188102
[TBL] [Abstract][Full Text] [Related]
17. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P;
Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256
[TBL] [Abstract][Full Text] [Related]
18. Early anti-TNF treatment in pediatric Crohn's disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients.
Olbjørn C; Nakstad B; Småstuen MC; Thiis-Evensen E; Vatn MH; Perminow G
Scand J Gastroenterol; 2014 Dec; 49(12):1425-31. PubMed ID: 25310799
[TBL] [Abstract][Full Text] [Related]
19. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
20. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn's disease treated with anti-TNF antibodies.
Katz LH; Kopylov U; Fudim E; Yavzori M; Picard O; Ungar B; Eliakim R; Ben-Horin S; Chowers Y
Clin Res Hepatol Gastroenterol; 2014 Sep; 38(4):491-8. PubMed ID: 24613656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
